Regular rituximab treatment lessens NMOSD relapses in real world
Regular rituximab treatment in neuromyelitis optica spectrum disorder resulted in less disability and fewer relapses, per a real word study.| Neuromyelitis News
Regular rituximab treatment in neuromyelitis optica spectrum disorder resulted in less disability and fewer relapses, per a real word study.| Neuromyelitis News
Off-label rituximab significantly reduces the risk of relapse and lessens disability in most NMOSD patients, a long-term study showed.| Neuromyelitis News
